PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.” Once granted, the patent wi ...

Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). The annual decline in eGFR slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the period following the last rilparencel injection. This 4.6 mL/min/1.73m2 per year difference was stat ...

Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company’s overall business strategy, Alzheimer’s disease program partnering ...

Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designationLaromestrocel HLHS program addres ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the August 31, 2025, PDUFA date for Deramiocel in Duchenne Muscular Dystrophy following successful FDA Pre-License Inspection SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas ...

Award celebrates bold leaders shaping the future through the world’s most ground-breaking companiesPOMPANO BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US has celebrated ambit ...

Home Run! Adia Med of Winter Park's AHCA Triumph Brings Insurance-Covered Healing to PatientsJune 16, 2025 9:00 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - June 16, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a leading innovator in regenerative medicine and nutritional supplements, is thrilled to announce that its state-of-the-art clinic, Adia Med of Winter Park, has received full approval from the Agency for Health Care Administration (AHCA). This milestone all ...

Informa Connect’s Global Longevity Summit continues to break new ground in the science of aging and human performance with the announcement of its 2025 keynote speaker, new advisory board appointments, and a call to act before the upcoming ticket price increase.GENEVA, SWITZERLAND, June 12, 2025 (GLOBE NEWSWIRE) -- Biogerontologist and epigenetic researcher Dr. Steve Horvath will headline the event as its keynote speaker and will be formally recognized as the recipient of the 2025 Global Longevity Award for ...

NASHVILLE, Tenn., June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group ("DHL"), one of the world's leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport.Concurrentl ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensureAdvisory Committee meeting scheduled for July 30, 2025Mid-cycle meeting recently completed with no significant issues or major deficiencies; late-cycle meeting planned for mid-JulyBiologics License Application remains under priority review with PDUFA target action date of August 31, 2025 SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnol ...